Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2026)

Agios Pharmaceuticals (AGIO) has 9 years of Gross Margin data on file, last reported at 93.3% in Q2 2026.

• Quarterly Gross Margin rose 697.0% year-over-year to 93.3% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 91.99% (up 381.0% YoY) and the FY2025 annual result came in at 88.26%, down 33.0% from the prior year.
• Gross Margin steadied at 93.3% in Q2 2026, from 93.64% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 93.64% in Q1 2026 to a low of 59.25% in Q1 2022.
• A 5-year average of 87.61% and a median of 90.27% in 2022 frame the typical range for Gross Margin.
• The widest YoY moves for Gross Margin: up 3087 bps in 2023, down 871 bps in 2023.
• Tracing AGIO's Gross Margin over 5 years: stood at 90.42% in 2022, then gained by 1 bps to 91.75% in 2023, then fell by 4 bps to 88.26% in 2024, then gained by 3 bps to 90.59% in 2025, then rose by 3 bps to 93.3% in 2026.
• The last three Gross Margin figures came in at 93.3% (Q2 2026), 93.64% (Q1 2026), and 90.59% (Q4 2025), per Business Quant data.